Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Lancet ; 1(8012): 625-6, 1977 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-66429

RESUMO

Fifteen patients with severe intermittent claudication were treated by therapeutic defibrination with subcutaneous injections of ancrod for 5 weeks. Mean plasma-fibrinogen was maintained below 50% of the initial value throughout the treatment period. This reduction in plasma-fibrinogen was accompanied by a parallel fall in whole-blood viscosity and a pronounced clinical improvement. Objective measurements showed maximum benefit on the 21st day of treatment, when the mean resting ankle/arm pressure index had increased by 37%, the post-exercise pressure index had increased by 50%, and the time taken for the pressure index to return to a resting value after a constant exercise had decreased by 33%. (The claudication-count had increased by 59%).


Assuntos
Ancrod/uso terapêutico , Endopeptidases/uso terapêutico , Claudicação Intermitente/tratamento farmacológico , Ancrod/administração & dosagem , Ancrod/farmacologia , Viscosidade Sanguínea/efeitos dos fármacos , Avaliação de Medicamentos , Fibrinogênio/antagonistas & inibidores , Seguimentos , Humanos , Injeções Subcutâneas , Claudicação Intermitente/sangue
2.
Br J Surg ; 64(1): 28-30, 1977 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-137762

RESUMO

A sensitive animal model was used to investigate treatment designed to improve vascular graft patency. A Dacron graft was inserted into the infrarenal vena cava of 30 rabbits. Half were treated with subcutaneous Arvin for 28 days after operation. This produced a significant lowering of the post operative plasma fibrinogen. The patency rate of the grafts in the treated rabbits was significantly greater than in the control rabbits.


Assuntos
Ancrod/farmacologia , Prótese Vascular , Endopeptidases/farmacologia , Fibrinogênio , Animais , Fibrinogênio/análise , Polietilenotereftalatos , Coelhos , Veia Cava Inferior/cirurgia
5.
Lancet ; 1(7973): 1317-8, 1976 Jun 19.
Artigo em Inglês | MEDLINE | ID: mdl-58309

RESUMO

The exact cause of Raynaud's phenomenon is still unknown. Since the principal feature of this condition is the precipitation of the attacks by cold, blood viscosity was measured in ten patients and in ten normal controls at 27 degrees C and 37 degrees C. The viscosity of the patients' blood was significantly higher (p less than 0.05) at 27 degrees C than that of the controls when measured at a low shear-rate (0.77 s-1). This, as well as the higher yield stress of the patients' blood, suggests that Raynaud's phenomenon may be caused by an abnormal local increase in the viscosity and yield stress of the blood in response to a fall in temperature.


Assuntos
Viscosidade Sanguínea , Doença de Raynaud/sangue , Adolescente , Adulto , Idoso , Aglutininas/análise , Feminino , Fibrinogênio/análise , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Raynaud/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...